Management of high-risk Myeloma: an evidence-based review of treatment strategies.

about

Management of high-risk Myeloma: an evidence-based review of treatment strategies.

Item

http://www.wikidata.org/entity/Q38874675

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Management of high-risk Myeloma: an evidence-based review of treatment strategies.

@en

type

Item

label

Management of high-risk Myeloma: an evidence-based review of treatment strategies.

@en

prefLabel

Management of high-risk Myeloma: an evidence-based review of treatment strategies.

@en

P1476

Management of high-risk Myeloma: an evidence-based review of treatment strategies.

@en

P2093

Marc-Steffen Raab

http://www.w3.org/2001/XMLSchema#string

Nicola Lehners

http://www.w3.org/2001/XMLSchema#string

Patrick J Hayden

http://www.w3.org/2001/XMLSchema#string

P2860

RNA-Seq: a revolutionary tool for transcriptomics

Prognostic significance of copy-number alterations in multiple myeloma

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Multiple myeloma in elderly patients: presenting features and outcome.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

P304

753-765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2016.1204908

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Goldschmidt

P577

2016-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27337562

http://www.w3.org/2001/XMLSchema#string